IDXG (Interpace Biosciences) Total Liabilities : $71.72 Mil (As of Sep. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Interpace Biosciences Total Liabilities?

Interpace Biosciences's Total Liabilities for the quarter that ended in Sep. 2024 was $71.72 Mil.

Interpace Biosciences's quarterly Total Liabilities declined from Mar. 2024 ($73.28 Mil) to Jun. 2024 ($72.00 Mil) and declined from Jun. 2024 ($72.00 Mil) to Sep. 2024 ($71.72 Mil).

Interpace Biosciences's annual Total Liabilities declined from Dec. 2021 ($80.85 Mil) to Dec. 2022 ($79.05 Mil) and declined from Dec. 2022 ($79.05 Mil) to Dec. 2023 ($74.69 Mil).

Interpace Biosciences Total Liabilities Historical Data

The historical data trend for Interpace Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Interpace Biosciences Total Liabilities Chart

Interpace Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

29.85

74.76

80.85

79.05

74.69

Interpace Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															76.93	74.69	73.28	72.00	71.72

Interpace Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Interpace Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	17.474	+	(5.715	+	51.504
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	74.69

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	13.021	-	-61.672
	=	74.69

Interpace Biosciences's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	18.769	+	(1.189	+	51.763
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	71.72

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	14.039	-	-57.682
	=	71.72

Interpace Biosciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Interpace Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (OTCPK:IDXG) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

PF42:Germany

Address

2001 Route 46, Suite 310, Waterview Plaza, Parsippany, NJ, USA, 07054

Website

https://www.interpace.com

Interpace Biosciences Inc is a fully integrated commercial company. It provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first line assays principally focused on early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology.

Executives

Christopher Mccarthy	officer: Principal Financial Officer	C/O INTERPACE BIOSCIENCES, INC., 300 INTERPACE PARKWAY; BLDG C, 1ST FLOOR, PARSIPPANY NJ 07054
Vijay Aggarwal	director	2320 SCIENTIFIC PARK DRIVE, WILMINGTON NC 28405
Thomas W. Burnell	director, officer: President and CEO	1355 PEACHTREE STREET, SUITE 1150, ATLANTA GA 30309
Peter H Kamin	10 percent owner	2720 DONALD ROSS ROAD, #311, PALM BEACH GARDENS FL 33410
Fred S. Knechtel	officer: Chief Financial Officer	REMY INTERNATIONAL, INC., 600 CORPORATION DR., PENDLETON IN 46064
Fortunato R. Rocca	director	C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE, VISTA CA 92081
Edward Chan	director	C/O 1315 CAPITAL II, L.P., 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
1315 Capital Ii, L.p.	10 percent owner	2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
Robert J. Gorman	director	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Laurence Mccarthy	director	2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Ampersand 2018 Limited Partnership	10 percent owner	55 WILLIAM STREET, SUITE 240, WELLESLEY MA 02481
Eric B. Lev	director, 10 percent owner	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Thomas John Freeburg	officer: Chief Accounting Officer	INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PKWY, BLDG. C, PARSIPPANY NJ 07054
Gregory Richard	officer: Chief Commerical Officer	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054
Felice Schnoll-sussman	director	C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054